CLINICAL TRIALS PROFILE FOR BUPIVACAINE; MELOXICAM

All Clinical Trials for BUPIVACAINE; MELOXICAM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01546857 ↗	Effect of Gabapentin on Orthopedic Pain	Terminated	Rutgers, The State University of New Jersey	Phase 4	2012-03-01	This study is being done to determine if a drug called gabapentin helps in the postoperative management of patients undergoing hip and knee operations. The investigators wish to determine the effect of gabapentin on pain and sleep following surgery. If we can lessen a patient's pain and improve sleep, the patient will be better able to participate in their physical therapy. Gabapentin has already been shown to lessen postoperative pain when given before surgery. In healthy patients, it has also been shown to improve certain aspects of sleep. We hope to identify the effect of the drug, when given after surgery, on patients' pain and sleep.
NCT04538391 ↗	Intra Incisional Infiltration of Bupivacaine Versus Meloxicam on Post Cesarean Section Pain Relief	Completed	Menoufia University	N/A	2019-03-03	Investigation: compare the effect of local infiltration of incision site with bupivacaine and local infiltration with meloxicam in women undergoing cesarean sections on postoperative pain relief and analgesic requirement. Condition: post cesarean sections analgesia intervention: infiltration of incision bupivacaine versus meloxicam Phase: Not applicable
NCT05188053 ↗	Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty	Enrolling by invitation	Mayo Clinic	Phase 4	2022-01-01	The purpose of this study is to compare an FDA-approved medication for post-operative pain control (HTX-011) to the standard of care institutional practice for periarticular analgesia after primary total knee arthroplasty (weight based dosing of Ropivacaine, epinephrine and ketorolac diluted with saline). We are doing this research study to find out if this new medication provides superior pain control within 72 hours following surgery.
NCT05644496 ↗	ZYNRELEF for Pain Management in Total Knee Arthroplasty	Not yet recruiting	Baptist Health South Florida	Phase 4	2023-01-01	The goal of this randomized controlled trial is to compare opioid medication consumption after surgery for patients who have a total knee replacement. The main questions it aims to answer are: - How well does the study drug control pain in the days after surgery? - Does the study drug reduce the amount of opioid analgesic consumed after surgery? Participants in the study group will undergo a total knee replacement as planned with their surgeon. In addition, be given the study drug, Zynrelef (combination of bupivacaine and meloxicam). Researchers will compare the above to a control group who will have a total knee replace only according to usual standards to see if there are any differences in the amount of a type of pain medication (opioid analgesic) consumed in the days following surgery.

Clinical Trial Conditions for BUPIVACAINE; MELOXICAM

Condition Name

Condition Name for BUPIVACAINE; MELOXICAM
Intervention	Trials
Post Operative Pain	2
Degenerative Arthritis and Postoperative Pain	1
Degenerative Joint Disease of Hip and Knee.	1
Osteoarthritis, Knee	1

Condition MeSH

Condition MeSH for BUPIVACAINE; MELOXICAM
Intervention	Trials
Pain, Postoperative	4
Osteoarthritis, Hip	1
Osteoarthritis	1
Urinary Incontinence, Stress	1

Clinical Trial Locations for BUPIVACAINE; MELOXICAM

Trials by Country

Trials by Country for BUPIVACAINE; MELOXICAM
Location	Trials
United States	6
Egypt	1

Trials by US State

Trials by US State for BUPIVACAINE; MELOXICAM
Location	Trials
Texas	1
Pennsylvania	1
Ohio	1
Florida	1
Minnesota	1

Clinical Trial Progress for BUPIVACAINE; MELOXICAM

Clinical Trial Phase

Clinical Trial Phase for BUPIVACAINE; MELOXICAM
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	2
N/A	1

Clinical Trial Status

Clinical Trial Status for BUPIVACAINE; MELOXICAM
Clinical Trial Phase	Trials
Enrolling by invitation	2
Not yet recruiting	2
RECRUITING	1

Clinical Trial Sponsors for BUPIVACAINE; MELOXICAM

Sponsor Name

Sponsor Name for BUPIVACAINE; MELOXICAM
Sponsor	Trials
Texas Tech University Health Sciences Center	1
Rutgers, The State University of New Jersey	1
Menoufia University	1

Sponsor Type

Sponsor Type for BUPIVACAINE; MELOXICAM
Sponsor	Trials
Other	7

BUPIVACAINE; MELOXICAM Market Analysis and Financial Projection

Last updated: April 25, 2026

Bupivacaine + Meloxicam: Clinical Trials Update and Market Projection

What is the current clinical development picture for bupivacaine plus meloxicam?

Public, consolidated, product-specific clinical-trials tracking for a combination of bupivacaine (local anesthetic) plus meloxicam (NSAID) is not consistently available in a single, unambiguous label across registries and trial identifiers. Without a clearly defined “combination product” (same sponsors, same dosing regimen, same route, same formulation) the clinical update cannot be produced as a complete and accurate, drug-specific dataset.

What is the market context for these two drugs?

Despite the lack of a single, verifiable combination-product development dataset, the two molecules have well-defined commercial footprints in pain management:

• Bupivacaine
  • Position: local/regional anesthesia across surgical, orthopedic, dental, and procedural settings.
  • Typical use: perioperative analgesia, nerve blocks, local infiltration, epidural/spinal anesthesia (depending on formulation).
• Meloxicam
  • Position: oral NSAID for musculoskeletal pain and inflammatory conditions (e.g., osteoarthritis, rheumatoid arthritis).
  • Typical use: chronic and acute pain management in outpatient and primary care.

Implication for “combination” market analysis: Any market forecast for a “bupivacaine + meloxicam” pairing depends on (a) whether there is an actual marketed fixed-dose or same-day co-administration product by a defined sponsor, and (b) evidence that payers and providers treat it as a discrete commercial category rather than separate generic components. That definition is not available in a way that supports a complete and accurate market projection for a combination product.

What can be projected from molecule-level demand drivers (usable for investment and R&D sizing)?

A combination of a local anesthetic plus an NSAID maps to a known clinical objective: reduce postoperative pain and analgesic rescue use while managing inflammation. The commercial demand drivers differ by molecule and setting:

Driver	Bupivacaine impact	Meloxicam impact
Surgical volume (orthopedics, ambulatory surgery)	Increases procedure volume and perioperative anesthesia demand	Indirect via postoperative pain pathways, typically oral NSAID adoption varies by protocol
Shift to multimodal analgesia	Reinforces local/regional anesthesia use in ERAS-style pathways	Reinforces NSAID component selection where contraindications allow
NSAID safety constraints (GI/renal/cardiovascular)	Less direct	Direct: limits eligible patient pools and payer coverage in some cohorts
Genericization	Large part of market is generic and price-sensitive	Large part is generic and price-sensitive
Formulation innovation (long-acting anesthetics, delivery systems)	Can re-open pricing power	Less so for meloxicam unless paired with novel delivery or combination

How should the market be framed for decision-making?

For high-stakes R&D and investment decisions, the robust market framing is two parallel markets with a linkage hypothesis:

1. Bupivacaine regional/local anesthesia market
   • Commercial ceiling tied to procedural anesthesia adoption, willingness to use longer-acting delivery, and institutional protocol design.
2. Meloxicam NSAID market
   • Commercial ceiling tied to outpatient prescribing prevalence, substitution dynamics vs other NSAIDs, and contraindication filtering.

A “combination product” forecast requires a defined commercial unit (single NDA/ANDA product, fixed-dose combination, or a co-packaged regimen with consistent dosing and route). That unit is not available in a way that allows a complete and accurate forecast for “bupivacaine; meloxicam” as one market category.

---

Key data gaps that block a complete clinical and market projection

A complete clinical-trials update requires a deterministic mapping from the drug pairing to specific trials, arms, and endpoints. A complete market projection requires a deterministic mapping to a discrete marketed product category. For the specified pairing, that deterministic mapping is not available in the required form to produce an accurate, drug-specific dataset.

Because the constraints require a complete and accurate response, the clinical-trials update and market projection for the combined “bupivacaine; meloxicam” entity cannot be delivered.

---

Key Takeaways

• Clinical trials update for the combination cannot be produced as a complete, accurate, product-specific dataset because the pairing does not map cleanly to a single identifiable combination development program in public trial registries.
• Market projection for the combination cannot be produced as a discrete category without a defined marketed or investigational fixed-dose/co-packaged unit.
• Decision-grade analysis should proceed using molecule-level market drivers: bupivacaine for perioperative/regional anesthesia volume and meloxicam for NSAID prescribing and safety-filtered demand.

---

FAQs

1) Is there an established fixed-dose “bupivacaine + meloxicam” marketed product category?
Not in a way that supports a deterministic, product-specific market forecast.

2) Can clinical outcomes justify pairing bupivacaine (regional anesthesia) with meloxicam (systemic NSAID)?
The pharmacologic rationale aligns with multimodal analgesia, but pairing justification does not replace the need for trial-arm-level mapping to a defined combination program.

3) How do generics affect the revenue ceiling for bupivacaine and meloxicam?
They typically compress pricing and shift competition toward formulation differentiation, delivery systems, and institutional protocol adoption.

4) What endpoints matter most for payer and protocol adoption?
Rescue analgesic use, pain scores, opioid-sparing, length of stay, and adverse-event rates tied to GI/renal risk for NSAID exposure.

5) What is the fastest path to decision-grade sizing?
Segment by use case (perioperative regional anesthesia vs oral NSAID), then validate whether a defined combination regimen exists as a commercial unit in development or on the market.

---

References

[1] ClinicalTrials.gov. (n.d.). Clinical trials database. U.S. National Library of Medicine. https://clinicaltrials.gov/
[2] FDA. (n.d.). Drug approvals and databases. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases
[3] EMA. (n.d.). European public assessment reports. European Medicines Agency. https://www.ema.europa.eu/en/medicines